EyePoint Pharmaceuticals, Inc. — Director's Dealing 2021

Nov 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2021-11-01

Reporting Person: Jones David Scott (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Stock Option (Right to Buy)	$11.47	A	10000.00	Acquired	2031-11-01	Common Stock (10000.00)	Direct

Footnotes

F1: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months